Balance Theory Raises $19.0M Series A for AI Cybersecurity Spend

DataBahn

Databahn is redefining how enterprises manage the explosion of security and operational data in the AI era. Our AI-powered data pipeline and fabric platform helps organizations securely collect, enrich, orchestrate, and optimize enterprise data—including security, application, observability, and IoT/OT telemetry—for analytics, automation, and AI. With native support for over 500 integrations and built-in enrichment capabilities, Databahn streamlines fragmented data workflows and reduces SIEM and infrastructure costs from day one. The platform requires no specialist training, enabling security and IT teams to extract insights in real time and adapt quickly to new demands. We've helped Fortune 500 and Global 2000 companies reduce data processing costs by over 60% and automate more than 80% of their data engineering workloads. Our founding team brings decades of experience in cybersecurity and infrastructure, having previously managed environments ingesting more than 12 petabytes of data per day. That deep domain expertise informs our bold, opinionated approach to solving one of the biggest pain points in enterprise infrastructure: how to unify and act on fragmented, fast-growing data streams. Purpose-built for scale, speed, and simplicity, Databahn replaces patchwork stacks with a single intuitive solution that accelerates time to value and turns security data from a cost center into a strategic asset.

Arrakis Security

Total visibility, policy enforcement, and real-time remediation over autonomous AI agents operating within enterprise infrastructure.

Ratio Therapeutics

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.